What Does the FDA Label Say About Tysabri and PML?

Latest update (2026-07)

Tysabri (natalizumab) PML injury claims continue to be evaluated based on individual monitoring and diagnosis records. [source]

Legacy of Health Information and the Shift to Occupational Exposure

If you or a loved one is taking Tysabri, you may have heard about the risk of progressive multifocal leukoencephalopathy (PML). This rare but serious brain infection is a known side effect, and the FDA label provides specific warnings and monitoring recommendations. Building on a long tradition of drug safety surveillance, this page reviews the key evidence from the label to help you understand the risks and what to discuss with your healthcare provider.

Tysabri and the Risk of Progressive Multifocal Leukoencephalopathy

Tysabri (natalizumab) is a monoclonal antibody used to treat multiple sclerosis and Crohn disease. Its prescribing information contains a boxed warning stating that Tysabri increases the risk of progressive multifocal leukoencephalopathy (PML), an opportunistic viral infection of the brain caused by the JC virus (JCV) that usually leads to death or severe disability (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). PML typically occurs only in patients who are immunocompromised, and the boxed warning emphasizes that healthcare professionals should monitor patients for any new sign or symptom suggestive of PML and withhold Tysabri immediately at the first such indication (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). Three factors are known to increase the risk of PML in Tysabri-treated patients: the presence of anti-JCV antibodies, longer treatment duration (especially beyond two years), and prior use of immunosuppressants (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). These factors should be considered in the context of expected benefit when initiating and continuing treatment (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). Because of the PML risk, Tysabri is available only through a restricted distribution program called the TOUCH Prescribing Program (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962).

Clinical Presentation and FDA Adverse Event Reports

PML is a severe demyelinating disease caused by JC polyomavirus, and its clinical presentation can include progressive neurological deficits such as cognitive impairment, motor weakness, gait disturbance, and visual changes. In a large retrospective cohort of 456 Italian PML patients observed between 1987 and 2024, the diagnosis was definite in 376 cases (82.4%) and clinico-radiological in 80 cases (17.6%) (https://pubmed.ncbi.nlm.nih.gov/40922664/). The study described changing clinical and laboratory characteristics of PML over time and according to underlying condition, highlighting the importance of early recognition (https://pubmed.ncbi.nlm.nih.gov/40922664/). FDA adverse-event reports for Tysabri frequently list neurological and general symptoms that could overlap with early PML presentation. The most commonly reported events include fatigue (19,150 reports), multiple sclerosis relapse (16,691 reports), headache (9,626 reports), gait disturbance (9,422 reports), memory impairment (7,895 reports), asthenia (7,852 reports), balance disorder (5,621 reports), hypoesthesia (5,343 reports), muscular weakness (4,535 reports), cognitive disorder (3,478 reports), and mobility decreased (3,769 reports) (https://api.fda.gov/drug/event.json?search=patient.drug.medicinalproduct:TYSABRI). These reports underscore the challenge of distinguishing PML from multiple sclerosis exacerbations or other adverse effects.

Mechanism, Warnings, and Legal Considerations

The mechanistic pathway linking Tysabri to PML involves its action as an alpha-4 integrin antagonist, which inhibits lymphocyte migration into the central nervous system. This immunosuppressive effect can allow JC virus reactivation and uncontrolled replication in the brain, leading to demyelination. The boxed warning explicitly states that Tysabri increases the risk of PML, and the warning is based on clinical trial and postmarketing data (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). Regarding the adequacy of warnings, the prescribing information includes a boxed warning, a medication guide, and the TOUCH program requirements. However, patients and healthcare providers must remain vigilant because PML can develop insidiously and progress rapidly. The warning advises monitoring for any new sign or symptom suggestive of PML and withholding Tysabri immediately at the first such indication (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). Despite these measures, cases of PML continue to be reported, and the outcome is often death or severe disability. For affected patients and their families, attorney-related considerations may include evaluating whether the risks of PML were adequately communicated and whether monitoring protocols were followed. The timeline between Tysabri exposure and documented PML harm can vary. Risk increases with longer treatment duration, especially beyond two years, and in patients who are anti-JCV antibody positive or have prior immunosuppressant use (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). Early diagnosis and discontinuation of Tysabri may improve outcomes, but PML often leads to irreversible neurological damage. In summary, Tysabri carries a well-documented risk of PML, a severe and often fatal brain infection. The prescribing information provides clear warnings and risk factors, but patients and clinicians must remain alert to early symptoms. Legal considerations may arise if there is evidence that warnings were insufficient or that monitoring was inadequate. The evidence supports that PML is a known adverse effect of Tysabri, with risk factors that should guide treatment decisions.

Important Notice

This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.

Frequently Asked Questions

What is Tysabri and why is it associated with PML?

Tysabri (natalizumab) is a monoclonal antibody used to treat multiple sclerosis and Crohn disease. It increases the risk of progressive multifocal leukoencephalopathy (PML), a severe brain infection caused by the JC virus, as indicated by its boxed warning (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962).

What are the risk factors for developing PML while on Tysabri?

Three key risk factors are: presence of anti-JCV antibodies, longer treatment duration (especially beyond two years), and prior use of immunosuppressants (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962).

What symptoms should prompt immediate medical evaluation for possible PML?

Symptoms include progressive neurological deficits such as cognitive impairment, motor weakness, gait disturbance, visual changes, and other signs like fatigue, headache, or balance disorder (https://api.fda.gov/drug/event.json?search=patient.drug.medicinalproduct:TYSABRI).

How is PML diagnosed and what is the prognosis?

Diagnosis is based on clinical presentation, MRI findings, and detection of JC virus DNA in cerebrospinal fluid. PML often leads to death or severe disability, though early discontinuation of Tysabri may improve outcomes (https://pubmed.ncbi.nlm.nih.gov/40922664/).

Does submitting information create an attorney-client relationship?

No. Submission requests an initial records screening only and does not create an attorney-client relationship.

Information Registry: individuals with documented Tysabri exposure and a confirmed Progressive Multifocal Leukoencephalopathy diagnosis may request an independent eligibility review. [Begin Assessment]

References

Request a Free Case Review

This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.